- Home
- STK vs GOSS Comparison
STK vs GOSS Comparison
Compare STK & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STK
- GOSS
- Stock Information
- Founded
- STK 2009
- GOSS 2015
- Country
- STK United States
- GOSS United States
- Employees
- STK N/A
- GOSS N/A
- Industry
- STK Investment Managers
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- STK Finance
- GOSS Health Care
- Exchange
- STK Nasdaq
- GOSS Nasdaq
- Market Cap
- STK 614.2M
- GOSS 501.2M
- IPO Year
- STK N/A
- GOSS 2019
- Fundamental
- Price
- STK $38.78
- GOSS $2.34
- Analyst Decision
- STK
- GOSS Strong Buy
- Analyst Count
- STK 0
- GOSS 6
- Target Price
- STK N/A
- GOSS $8.60
- AVG Volume (30 Days)
- STK 38.2K
- GOSS 3.0M
- Earning Date
- STK 01-01-0001
- GOSS 11-05-2025
- Dividend Yield
- STK 6.60%
- GOSS N/A
- EPS Growth
- STK N/A
- GOSS N/A
- EPS
- STK N/A
- GOSS N/A
- Revenue
- STK N/A
- GOSS $40,237,000.00
- Revenue This Year
- STK N/A
- GOSS N/A
- Revenue Next Year
- STK N/A
- GOSS $16.11
- P/E Ratio
- STK N/A
- GOSS N/A
- Revenue Growth
- STK N/A
- GOSS N/A
- 52 Week Low
- STK $24.95
- GOSS $0.66
- 52 Week High
- STK $34.31
- GOSS $3.60
- Technical
- Relative Strength Index (RSI)
- STK 64.29
- GOSS 46.42
- Support Level
- STK $38.59
- GOSS $2.20
- Resistance Level
- STK $39.74
- GOSS $2.52
- Average True Range (ATR)
- STK 0.64
- GOSS 0.15
- MACD
- STK 0.06
- GOSS 0.01
- Stochastic Oscillator
- STK 72.73
- GOSS 52.33
About STK Columbia Seligman Premium Technology Growth Fund Inc
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services. Columbia Management Investment Advisers, LLC serves as the investment manager to the fund.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.